Bristol-Myers Squibb Company (BMY) Free cash flow 2016–2025
Bristol-Myers Squibb Company (BMY) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$12.8BFY2025 · since FY2016: $1.8B → $12.8B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $12.8B | -7.9% |
| FY2024 | $13.9B | +10.2% |
| FY2023 | $12.7B | +5.9% |
| FY2022 | $11.9B | -21.6% |
| FY2021 | $15.2B | +14.5% |
| FY2020 | $13.3B | +80.3% |
| FY2019 | $7.4B | +20.6% |
| FY2018 | $6.1B | +44.9% |
| FY2017 | $4.2B | +129.0% |
| FY2016 | $1.8B | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice